We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+20.89%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$6.13B
AUM Growth
+$563M
Cap. Flow
-$172M
Cap. Flow %
-2.8%
Top 10 Hldgs %
24.72%
Holding
175
New
20
Increased
65
Reduced
40
Closed
23

Top Buys

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$59.7M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$54.7M
3
LXEO icon
Lexeo Therapeutics
LXEO
+$37.3M
4
MNDY icon
monday.com
MNDY
+$32.9M
5
XMTR icon
Xometry
XMTR
+$28.5M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$79.8M
2
EXAS
Exact Sciences
EXAS
+$51.4M
3
SHLS icon
Shoals Technologies Group
SHLS
+$42.6M
4
ASND icon
Ascendis Pharma A/S
ASND
+$39.3M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$39.2M

Sector Composition

Rank Sector Weight
1 Healthcare 39.38%
2 Technology 24.68%
3 Industrials 16.87%
4 Consumer Discretionary 8.76%
5 Communication Services 2.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDW icon
51
CDW
CDW
$18.6B
$41M 0.67%
180,520
+11,810
+7% +$2.5M
DVAX
52
DELISTED
Dynavax Technologies
DVAX
$40.5M 0.66%
2,893,435
+1,468,435
+103% +$20.4M
LXEO icon
53
Lexeo Therapeutics
LXEO
$342M
$40.3M 0.66%
+3,002,831
New +$37.3M
LSCC icon
54
Lattice Semiconductor
LSCC
$17.7B
$38.3M 0.63%
555,329
+127,326
+30% +$8.46M
PCVX icon
55
Vaxcyte
PCVX
$8.08B
$38.1M 0.62%
607,206
+214,206
+55% +$11.1M
CRNX icon
56
Crinetics Pharmaceuticals
CRNX
$8.85B
$37.7M 0.62%
1,059,633
+40,851
+4% +$1.25M
SPT icon
57
Sprout Social
SPT
$509M
$36M 0.59%
586,739
-402,182
-41% -$21.2M
NARI
58
DELISTED
Inari Medical, Inc. Common Stock
NARI
$33.3M 0.54%
512,914
– –
FERG icon
59
Ferguson
FERG
$43.9B
$32.9M 0.54%
170,362
+24,360
+17% +$4.11M
ORLY icon
60
O'Reilly Automotive
ORLY
$72.4B
$29.6M 0.48%
466,605
+5,625
+1% +$355K
SHW icon
61
Sherwin-Williams
SHW
$83.7B
$29.4M 0.48%
94,322
+1,205
+1% +$324K
SNPS icon
62
Synopsys
SNPS
$71.3B
$29M 0.47%
56,332
-22,673
-29% -$11.6M
BBIO icon
63
BridgeBio Pharma
BBIO
$16.1B
$28.9M 0.47%
716,927
– –
BPMC
64
DELISTED
Blueprint Medicines
BPMC
$28.8M 0.47%
312,374
-126,126
-29% -$8.17M
AJG icon
65
Arthur J. Gallagher & Co
AJG
$65.9B
$28.4M 0.46%
126,186
+17,627
+16% +$4.18M
WMB icon
66
Williams Companies
WMB
$86.7B
$27.7M 0.45%
796,413
+10,196
+1% +$358K
AXSM icon
67
Axsome Therapeutics
AXSM
$12.1B
$27.6M 0.45%
346,712
– –
VRNA
68
DELISTED
Verona Pharma
VRNA
$27.4M 0.45%
1,377,781
+527,781
+62% +$7.79M
KRRO icon
69
Korro Bio
KRRO
$151M
$26.2M 0.43%
546,325
+474,383
+659% +$15.6M
WDAY icon
70
Workday
WDAY
$39B
$26.1M 0.43%
94,464
+1,044
+1% +$249K
ISRG icon
71
Intuitive Surgical
ISRG
$126B
$25.9M 0.42%
76,694
+295
+0.4% +$87.9K
PNR icon
72
Pentair
PNR
$10.6B
$25.7M 0.42%
354,141
+23,891
+7% +$1.54M
IRTC icon
73
iRhythm Holdings
IRTC
$3.91B
$25.6M 0.42%
239,135
– –
INSP icon
74
Inspire Medical Systems
INSP
$1.44B
$25.4M 0.42%
125,090
– –
ACAD icon
75
Acadia Pharmaceuticals
ACAD
$4.55B
$25.3M 0.41%
+809,391
New +$19.3M
1 2
3
4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q4 2023 Portfolio in Review

As of Q4 2023, Eventide Asset Management held 175 positions worth $6.13B, up 10% from $5.56B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Eventide Asset Management's Q4 2023 filing shows 20 new, 65 increased, 40 reduced and 23 closed positions. Its largest new stake was Lexeo Therapeutics: 3,002,831 shares worth $40.3M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $79.8M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 41% a quarter earlier, followed by Technology and Industrials.

  • Eventide Asset Management's largest Q4 2023 buy was Lexeo Therapeutics: 3,002,831 shares worth $40.3M.
  • Eventide Asset Management added most to Celldex Therapeutics in Q4 2023, an estimated $59.7M increase.
  • Eventide Asset Management's biggest Q4 2023 reduction was Exact Sciences, cutting an estimated $51.4M.
  • Eventide Asset Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $79.8M.
  • Eventide Asset Management's ten largest holdings make up 25% of its $6.13B portfolio in Q4 2023.
  • Eventide Asset Management opened 20 new positions and closed 23 in Q4 2023.
  • Eventide Asset Management's portfolio value rose 10% quarter-over-quarter to $6.13B.

Based on Eventide Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.